EUVIMEDEUVIMED entdecken
Vergleichsstudie

Risk of Upper Limb Tendinopathy and Tenosynovitis Comparison Between Glucagon Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors

Pei-Yun Chen iD, Sunny Ssu-Yu Chen iD, Renin Chang iD, Mei-Chia Chou, Pili Chih-Min Mao

International Journal of Rheumatic Diseases · 2026-11 · 29 (11)

DOI: 10.1111/1756-185x.70900 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 13.11.2026. Verfasst von Pei-Yun Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Transporter 2 Inhibitors, Tendinopathy. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study compared the risk of common upper limb tendinopathy and tenosynovitis between new users of GLP‐1RAs and SGLT2is among patients with Type 2 diabetes mellitus (T2DM).

Methods

A retrospective cohort utilizing data from the TriNetX research network was performed. We identified individuals with T2DM who initiated either GLP‐1RAs or SGLT2is. GLP‐1RAs users were propensity‐score matched (PSM) 1:1 to SGLT2is users based on demographic and relevant clinical covariates. Cox proportional hazards models, Kaplan–Meier and subgroup analyses were employed to estimate the relative hazards of common upper limb tendinopathy and tenosynovitis between the two groups.

Results

The crude cohort included 37 606 GLP‐1RAs users and 16 695 SGLT2is users. After PSM ( n = 15 303 per group), GLP‐1RAs users demonstrated higher risks of trigger finger (HR 1.172, 95% CI: 1.053–1.305) and medial epicondylitis (HR 1.518, 95% CI: 1.078–2.137) compared to SGLT2is users.

Conclusions

GLP‐1RAs use was associated with higher observed risks of trigger finger and medial epicondylitis compared to SGLT2is use in patients with T2DM. However, given the observational nature of the study, further prospective studies are needed for validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsTendinopathyTenosynovitisIncretinsHumansFemaleRetrospective StudiesRisk FactorsMaleMiddle AgedRisk AssessmentAgedTime FactorsDatabases, FactualTreatment OutcomeUpper ExtremityGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

glucagon like peptide‐1 receptor agonistssodium‐glucose cotransporter 2 inhibitorsupper limb tendinopathy and tenosynovitis

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsIncretinsGLP1R protein, humanGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of Physical Medicine and Rehabilitation, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
  • School of Medicine, National Defense Medical University, Taipei, Taiwan.
  • Department of Physical Medicine and Rehabilitation, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Institute of Neuroscience, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.

ORCID-Profile: Pei-Yun Chen, Sunny Ssu-Yu Chen, Renin Chang

Zitieren

APA

Chen, P. Y., Chen, S. S., Chang, R., Chou, M. C., & Mao, P. C. (2026). Risk of Upper Limb Tendinopathy and Tenosynovitis Comparison Between Glucagon Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors. International Journal of Rheumatic Diseases, 29(11). https://doi.org/10.1111/1756-185x.70900

Vancouver

Chen PY, Chen SS, Chang R, Chou MC, Mao PC. Risk of Upper Limb Tendinopathy and Tenosynovitis Comparison Between Glucagon Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors. International Journal of Rheumatic Diseases. 2026;29(11). doi:10.1111/1756-185x.70900

BibTeX
@article{Chen2026,
  author = {Chen, Pei-Yun and Chen, Sunny Ssu-Yu and Chang, Renin and Chou, Mei-Chia and Mao, Pili Chih-Min},
  title = {Risk of Upper Limb Tendinopathy and Tenosynovitis Comparison Between Glucagon Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter 2 Inhibitors},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  volume = {29},
  number = {11},
  doi = {10.1111/1756-185x.70900}
}
Kostenlos starten →